GHK-Cu Biocosmetic Cream (GHK-Cu 3% / Estriol 0.003%)

Research Summary

Mechanism & Physiological Role

GHK-Cu paired with estriol at low percentage. Estriol is 16-alpha-hydroxy estradiol, and that third hydroxyl shortens how long it occupies the estrogen receptor, which is most of what separates it from estradiol.

Clinical & Research Applications

Discussed in the dermatology literature on topical estrogen and in the endocrine literature on compounded hormone preparations, where consensus statements describe the evidence base and the regulatory position together.

Biosynthesis, Handling & Sourcing

Estriol is the third of the classical estrogens and its name is its formula: three hydroxyl groups, at carbon 3, at 16-alpha and at 17-beta. Estradiol carries two of them and estrone one alongside a ketone. That extra 16-alpha hydroxyl is a small change and a decisive one, because it lowers affinity for both estrogen receptor subtypes and, more consequentially, shortens how long the molecule remains bound once it arrives. Occupancy time rather than affinity alone governs the transcriptional response, which is why the endocrine literature describes estriol as short-acting rather than simply weak.

Two consequences follow that are easy to miss. Because estriol competes for the same site while producing a briefer response, it can behave as a partial antagonist when estradiol is also present, so what it does depends on what else is in the system rather than being fixed. Its natural context is pregnancy: estriol is produced in quantity by the fetoplacental unit, starting from fetal adrenal DHEA sulfate, which is 16-alpha hydroxylated in the fetal liver before the placenta aromatises it. The same DHEA described on the DHEA page is the upstream substrate.

The regulatory position needs stating plainly rather than left to inference. There is no FDA-approved estriol drug product in the United States. Estriol is approved and marketed in parts of Europe but not here, so any estriol preparation dispensed in the US is by definition a compounded one. Professional consensus statements on compounded bioidentical hormone therapy, including from the American College of Obstetricians and Gynecologists, describe the evidence base as limited and note that compounded preparations are not held to the manufacturing and labelling standards approved products must meet. A cream containing an estrogen is functioning as a drug however it is marketed, and that is the frame to apply when deciding whether to stock it.

What topical estrogen does in skin has its own small literature. A systematic review published in 2026 examined topical estrogen for skin ageing and characterised the available evidence as limited in both quantity and quality. The concentration here is very low, three thousandths of one percent, and concentration is the entire question for whether a topical hormone stays local: the lower it goes the smaller the systemic exposure, and by the same arithmetic the smaller everything else. That trade belongs to the prescriber rather than to the formulation.

Handling is governed by the copper rather than the steroid, and that chemistry runs the same way across every GHK-Cu preparation: chelating agents compete for the metal, reducing agents change its oxidation state, and the blue tint of an intact complex is a visible check. It is covered in full on the GHK-Cu hair solution page and not repeated here. This is a non-sterile topical cream compounded under USP General Chapter 795, carrying a beyond-use date assigned at preparation. This composition is not FDA-approved, compounded medications are not FDA-approved finished drug products, and nothing on this page is a statement that any preparation is suitable for a given patient.